Wikisage, the free encyclopedia of the second generation, is digital heritage
Epilepsy: Difference between revisions
(→wLinks: doose) |
mNo edit summary |
||
Line 83: | Line 83: | ||
[http://www.scholarpedia.org/w/index.php?title=Models_of_epilepsy&oldid=140675 Models of epilepsy] | [http://www.scholarpedia.org/w/index.php?title=Models_of_epilepsy&oldid=140675 Models of epilepsy] | ||
[https://www.frontiersin.org/articles/10.3389/fphar.2017.00661/full purinergic signalling:therapeutic developments] | |||
[[Lennox–Gastaut_syndrome|Lennox-Gastaut Syndrome]] | [[Lennox–Gastaut_syndrome|Lennox-Gastaut Syndrome]] |
Revision as of 01:19, 17 October 2017
Classification of ethiology could divided in four categories:
- idiopathic epilepsy
- symptomatic epilepsy
- provoked epilepsy
- cryptogenic epilepsy
[1] It is difficult to distinguish between genetic and cryptogenic syndromes.
Morbility data is difficult to interpret when WHO[2] states 50-70 millions persons[3] suffers epilepsy[4]
nonadherence appears to be associated with increased health care costs, nevertheless XR-medicine appears as strategy to overcome compliance with AED[5]
Medicines | ||||
type | ,,, | ,,,, | ||
INN | Generic | slow release | ||
carbamazepine | normal | xr | ||
lamotrigine | normal | Lamictal XR[6] | ||
levetiracetam | normal | xr | ||
oxcarbazepine | oxcarbazepine | xr | ||
phenytoin | ... | xr | ||
valproate | xr | |||
topiramate | xr | |||
AED |
Diverse Mechanisms of Antiepileptic Drugs in the Development Pipeline
ILAE Classification
[7] [8] [9] [10] ILAE Overview
See also
A new perspective for Epileptic Disorders
Links
Epilepsies: diagnosis and management clinical guide
Prevalence and cost of nonadherence with antiepileptic drugs in an adult managed care population
The Efficacy of Leviteracetam versus Carbamazepine for Epilepsy: A Meta-Analysis
The intrinsic severity hypothesis of pharmacoresistance to antiepileptic drugs
purinergic signalling:therapeutic developments
References: |
|